Effects of l-Tyrosine on working memory and inhibitory control are determined by DRD2 genotypes: A randomized controlled trial

Colzato, Lorenza S.; Steenbergen, Laura; Sellaro, Roberta; Stock, Ann‐Kathrin; Arning, Larissa; Beste, Christian

doi:10.1016/j.cortex.2016.06.010

Cited by 30 publications

(30 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous attempts to boost DA transmission in healthy adults 59, 60 might not improve response inhibition performance because most healthy adults should presumably already have optimal levels of DA to support task performance, based on the inverted U-shape theory of dopaminergic function in cognition. 65 In support, Colzato et al 66 found that L-Tyrosine (DA precursor) administration improved SSRT only in the subset of healthy adults with the T/T polymorphism of the dopamine D2 receptor, which confers low levels of striatal DA. These considerations highlight the need for systematic assessment of DA’s role in response inhibition in various populations, using a variety of behavioral tasks and medication statuses.…”

Section: Discussionmentioning

confidence: 94%

Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects

Manza

Amandola

Tatineni

et al. 2017

npj Parkinson's Disease

View full text Add to dashboard Cite

Parkinson’s disease is a neurodegenerative disorder involving the basal ganglia that results in a host of motor and cognitive deficits. Dopamine-replacement therapy ameliorates some of the hallmark motor symptoms of Parkinson’s disease, but whether these medications improve deficits in response inhibition, a critical executive function for behavioral control, has been questioned. Several studies of Parkinson’s disease patients “on” and “off” (12-h withdrawal) dopaminergic medications suggested that dopamine-replacement therapy did not provide significant response inhibition benefits. However, these studies tended to include patients with moderate-to-advanced Parkinson’s disease, when the efficacy of dopaminergic drugs is reduced compared to early-stage Parkinson’s disease. In contrast, a few recent studies in early-stage Parkinson’s disease report that dopaminergic drugs do improve response inhibition deficits. Based on these findings, we hypothesized that Parkinson’s disease duration interacts with medication status to produce changes in cognitive function. To investigate this issue, we conducted a meta-analysis of studies comparing patients with Parkinson’s disease and healthy controls on tests of response inhibition (50 comparisons from 42 studies). The findings supported the hypothesis; medication benefited response inhibition in patients with shorter disease duration, whereas “off” medication, moderate deficits were present that were relatively unaffected by disease duration. These findings support the role of dopamine in response inhibition and suggest the need to consider disease duration in research of the efficacy of dopamine-replacement therapy on cognitive function in Parkinson’s disease.

show abstract

Section: Discussionmentioning

confidence: 94%

Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects

Manza

Amandola

Tatineni

et al. 2017

npj Parkinson's Disease

View full text Add to dashboard Cite

show abstract

“…The involvement of dopamine in regulating cognitive flexibility particularly in animal studies is well-documented [15]. In humans, studies in which brain dopamine levels were enhanced by the administration of the dopamine precursor tyrosine have shown that increases in dopamine are beneficial to cognitive control [16,17] and, importantly, cognitive flexibility [18].…”

Section: Introductionmentioning

confidence: 99%

Catecholaminergic modulation of indices of cognitive flexibility: A pharmaco-tDCS study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, after meta-analysis, the signification was lost [81]. C957T SNV's previous positive association with working memory function [87][88][89], and response inhibition [87,88,90] were also negative after a meta-analysis, while cognitive flexibility was still associated. Some of these inconsistencies could be attributed to both the heterogeneity of the executive function tasks used and the variability of the populations investigated [81].…”

Section: The Functional Relationship Of Ankk1 and Drd2mentioning

confidence: 95%

Ankyrin Repeat and Kinase Domain Containing 1 Gene, and Addiction Vulnerability

Koeneke

Ponce

Troya-Balseca

et al. 2020

IJMS

View full text Add to dashboard Cite

The TaqIA single nucleotide variant (SNV) has been tested for association with addictions in a huge number of studies. TaqIA is located in the ankyrin repeat and kinase domain containing 1 gene (ANKK1) that codes for a receptor interacting protein kinase. ANKK1 maps on the NTAD cluster along with the dopamine receptor D2 (DRD2), the tetratricopeptide repeat domain 12 (TTC12) and the neural cell adhesion molecule 1 (NCAM1) genes. The four genes have been associated with addictions, although TTC12 and ANKK1 showed the strongest associations. In silico and in vitro studies revealed that ANKK1 is functionally related to the dopaminergic system, in particular with DRD2. In antisocial alcoholism, epistasis between ANKK1 TaqIA and DRD2 C957T SNVs has been described. This clinical finding has been supported by the study of ANKK1 expression in peripheral blood mononuclear cells of alcoholic patients and controls. Regarding the ANKK1 protein, there is direct evidence of its location in adult and developing central nervous system. Together, these findings of the ANKK1 gene and its protein suggest that the TaqIA SNV is a marker of brain differences, both in structure and in dopaminergic function, that increase individual risk to addiction development.

show abstract

Effects of l-Tyrosine on working memory and inhibitory control are determined by DRD2 genotypes: A randomized controlled trial

Cited by 30 publications

References 50 publications

Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects

Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects

Catecholaminergic modulation of indices of cognitive flexibility: A pharmaco-tDCS study

Ankyrin Repeat and Kinase Domain Containing 1 Gene, and Addiction Vulnerability

Contact Info

Product

Resources

About